Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382262 · ClinicalTrials.gov registry record · Phase 2
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
A Phase 2 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT03382262 is a Phase 2 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT03382262, a Phase 2 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip
Interventions
- DRUG FX006 32 mg
- DRUG TAcs 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2018-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382262
The ClinicalTrials.gov registry entry for NCT03382262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FX006 32 mg is the first listed.
NCT03382262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382262 about?
NCT03382262 is a clinical study titled "Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip". This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip
What is the current status of trial NCT03382262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-12-18. Estimated completion is 2018-10-09.
What interventions are being tested in trial NCT03382262?
The interventions under investigation include: FX006 32 mg (DRUG), TAcs 40 mg (DRUG).
Who is sponsoring clinical trial NCT03382262?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.